Gold prices slide further as easing US-China tensions curb haven demand
Adaptive Biotechnologies Corp (ADPT), with a market capitalization of $2.61 billion, has reached a significant milestone as its stock hit a 52-week high of 17.25 USD. According to InvestingPro analysis, the stock’s RSI indicates overbought territory, suggesting investors should monitor the situation carefully. This achievement marks a notable point in the company’s market performance, reflecting investor confidence and positive market sentiment. Over the past year, the company’s stock has experienced a remarkable increase, with a 1-year return exceeding 256%. The company has shown strong momentum with revenue growth of 21.6% and impressive returns across multiple timeframes. InvestingPro subscribers have access to 12 additional key insights about ADPT, including detailed analysis of its financial health and growth prospects through comprehensive Pro Research Reports.
In other recent news, Adeptus Biotechnologies has announced the termination of its Strategic Collaboration and License Agreement with Genentech, effective February 9, 2026. This move will release Adeptus from exclusivity obligations related to cell therapies in oncology, enabling the company to pursue new licensing opportunities with other biopharmaceutical firms. Piper Sandler has raised its price target for Adeptus to $20.00, maintaining an Overweight rating, following a survey highlighting the company’s strong performance in minimal residual disease (MRD) detection. Morgan Stanley also increased its price target to $11.00, citing strong momentum in clonoSEQ volume and average selling price. BTIG has reiterated its Buy rating and a $14.00 price target, emphasizing the potential benefits of the Genentech deal termination. Piper Sandler previously raised its price target to $15.00, noting a 30% revenue growth rate driven by significant volume acceleration in the MRD business. These developments reflect a period of strategic adjustments and growth prospects for Adeptus Biotechnologies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.